Methylene blue (3,7-bis(dimethylamino)phenothiazine-5-ium chloride) is a synthetic phenothiazine dye with a history spanning over 150 years — from its origins as a textile dye and the first synthetic drug in modern medicine to its contemporary rediscovery as a mitochondrial enhancer, neuroprotective agent, and cognitive enhancer. It is unique among nootropics in that it functions primarily as an electron carrier in the mitochondrial electron transport chain, with the capacity to physically accept and donate electrons in place of normal carrier proteins when they become dysfunctional.
At low doses (typically 0.5–4mg/kg of body weight, or approximately 35–280mg for a 70kg adult, though nootropic use often targets the lower end of this range or below), methylene blue acts as an alternative electron acceptor in the mitochondrial respiratory chain, bypassing Complex I-III dysfunction, reducing oxidative stress, enhancing ATP production, and exerting a cytoprotective effect in metabolically stressed neurons. Multiple rodent studies demonstrate improvements in learning, memory consolidation, and anxiolytic effects at these doses. A small number of human studies have found cognitive benefits and enhanced memory consolidation, particularly in aging populations.
However, methylene blue has a critically important hormetic dose-response: at higher doses (>10mg/kg), it reverses from neuroprotective to pro-oxidant, inhibiting mitochondrial function rather than supporting it. This means dose selection is not merely about calibrating effects — it determines whether the compound is beneficial or harmful.
A second critical safety consideration is the risk of serotonin syndrome when methylene blue is combined with serotonergic medications. Methylene blue is a potent MAO inhibitor (particularly MAO-A), and its combination with SSRIs, SNRIs, tricyclic antidepressants, tramadol, or any serotonergic drug can produce life-threatening serotonin syndrome. This interaction is sufficiently serious that the FDA issued a safety communication in 2011 specifically warning about it. This is not a theoretical risk — multiple cases of serious serotonin syndrome following intravenous methylene blue administration in patients on serotonergic medications have been documented.